Loading
A phase 2 trial of SSGJ-705 in advanced solid tumours, run by Shenyang Sunshine Pharmaceutical Co., LTD., now recruiting.
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors is a phase 2 interventional study registered as NCT07022002 by Shenyang Sunshine Pharmaceutical Co., LTD., with 340 participants planned, started 2025-07-30 and due to reach its primary completion in 2026-12-31. Interventions recorded: SSGJ-705, PD-1/L1 inhibitor combined with chemotherapy and SSGJ-705 combined with chemotherapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SSGJ-705, 3SBio, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares 3SBio, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares 3SBio and the tag pipeline.
Shares 3SBio and the tag pipeline.
Shares 3SBio and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/